Optimization of Highly Kinase Selective Bis-anilino Pyrimidine PAK1 Inhibitors.

Abstract

Group I p21-activated kinase (PAK) inhibitors are indicated as important in cancer progression, but achieving high kinase selectivity has been challenging. A bis-anilino pyrimidine PAK1 inhibitor was identified and optimized through structure-based drug design to improve PAK1 potency and achieve high kinase selectivity, giving in vitro probe compound AZ13705339 (18). Reduction of lipophilicity to lower clearance afforded AZ13711265 (14) as an in vivo probe compound with oral exposure in mouse. Such probes will allow further investigation of PAK1 biology.

• Authors: William McCoull, Edward J Hennessy, Kevin Blades, Claudio Chuaqui, James E Dowling, Andrew D Ferguson, Frederick W Goldberg, Nicholas Howe, Christopher R Jones, Paul D Kemmitt, Gillian Lamont, Jeffrey G Varnes, Richard A Ward, Bin Yang
• Journal: ACS medicinal chemistry letters (ACS Med Chem Lett) Vol. 7 Issue 12 Pg. 1118-1123 (Dec 08 2016) ISSN: 1948-5875 [Print] United States
• PMID: 27994749 (Publication Type: Journal Article)